CRISPR/Cas9:

Emir Begagić1, Hakija Bečulić2,3, Nermin Đuzić4

  • 1Department of General Medicine, School of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina.

Biomedicines
|January 26, 2024
PubMed
概括

克里斯普尔/卡斯9基因编辑通过准参与细胞周期,微环境和治疗耐药性的基因,为质母细胞瘤 (GBM) 提供了新的见解. 这项技术显示出开发新型针对性治疗对抗侵略性脑瘤的前景.